Adaptive Biotechnologies (ADPT) Operating Leases (2020 - 2026)

Adaptive Biotechnologies has reported Operating Leases for 7 years, with the latest figure at $69.1 million in Q1 2026.

• Quarterly Operating Leases fell 9.58% year-over-year to $69.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.1 million (down 9.58% YoY) and the FY2025 annual result came in at $70.2 million, down 11.27% from the prior year.
• Operating Leases eased to $69.1 million in Q1 2026 per ADPT's latest filing, from $70.2 million in the prior quarter.
• Over five years, Operating Leases peaked at $105.0 million in Q1 2022 and troughed at $69.1 million in Q1 2026.
• A 5-year average of $86.7 million and a median of $86.9 million in 2024 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2025: Operating Leases climbed 10.21% in 2022, then retreated 12.04% in 2025.
• Over 5 years, Operating Leases stood at $98.8 million in 2022, then dropped by 9.5% to $89.4 million in 2023, then retreated by 11.46% to $79.1 million in 2024, then retreated by 11.27% to $70.2 million in 2025, then decreased by 1.58% to $69.1 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $69.1 million, $70.2 million, and $72.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.